Phase II trial of mitoxantrone and cisplatin in advanced non-small-cell lung cancer

Lynn G Feun, Niramol Savaraj, Jeanine Solomon, Amy Liebmann, Judith Hurley

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Because in vitro data suggest that mitoxantrone may be synergistic with cisplatin, a Phase II trial of mitoxantrone and cisplatin was conducted in patients with advanced or metastatic non-small-cell lung cancer (NSLC). Twenty-four patients were evaluable for response. Toxicity was tolerable. Partial responses occurred in three patients (13%). This response rate is similar to that reported for cisplatin alone in NSLC. Mitoxantrone did not improve the response rate when combined with cisplatin for patients with advanced NSLC.

Original languageEnglish
Pages (from-to)190-192
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume19
Issue number2
DOIs
StatePublished - Apr 1 1996

Fingerprint

Mitoxantrone
Non-Small Cell Lung Carcinoma
Cisplatin

Keywords

  • Cisplatin
  • Lung cancer
  • Mitoxantrone

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II trial of mitoxantrone and cisplatin in advanced non-small-cell lung cancer. / Feun, Lynn G; Savaraj, Niramol; Solomon, Jeanine; Liebmann, Amy; Hurley, Judith.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 19, No. 2, 01.04.1996, p. 190-192.

Research output: Contribution to journalArticle

@article{47e16f60bfba469fb80b9ccac1dd4bf0,
title = "Phase II trial of mitoxantrone and cisplatin in advanced non-small-cell lung cancer",
abstract = "Because in vitro data suggest that mitoxantrone may be synergistic with cisplatin, a Phase II trial of mitoxantrone and cisplatin was conducted in patients with advanced or metastatic non-small-cell lung cancer (NSLC). Twenty-four patients were evaluable for response. Toxicity was tolerable. Partial responses occurred in three patients (13{\%}). This response rate is similar to that reported for cisplatin alone in NSLC. Mitoxantrone did not improve the response rate when combined with cisplatin for patients with advanced NSLC.",
keywords = "Cisplatin, Lung cancer, Mitoxantrone",
author = "Feun, {Lynn G} and Niramol Savaraj and Jeanine Solomon and Amy Liebmann and Judith Hurley",
year = "1996",
month = "4",
day = "1",
doi = "10.1097/00000421-199604000-00021",
language = "English",
volume = "19",
pages = "190--192",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Phase II trial of mitoxantrone and cisplatin in advanced non-small-cell lung cancer

AU - Feun, Lynn G

AU - Savaraj, Niramol

AU - Solomon, Jeanine

AU - Liebmann, Amy

AU - Hurley, Judith

PY - 1996/4/1

Y1 - 1996/4/1

N2 - Because in vitro data suggest that mitoxantrone may be synergistic with cisplatin, a Phase II trial of mitoxantrone and cisplatin was conducted in patients with advanced or metastatic non-small-cell lung cancer (NSLC). Twenty-four patients were evaluable for response. Toxicity was tolerable. Partial responses occurred in three patients (13%). This response rate is similar to that reported for cisplatin alone in NSLC. Mitoxantrone did not improve the response rate when combined with cisplatin for patients with advanced NSLC.

AB - Because in vitro data suggest that mitoxantrone may be synergistic with cisplatin, a Phase II trial of mitoxantrone and cisplatin was conducted in patients with advanced or metastatic non-small-cell lung cancer (NSLC). Twenty-four patients were evaluable for response. Toxicity was tolerable. Partial responses occurred in three patients (13%). This response rate is similar to that reported for cisplatin alone in NSLC. Mitoxantrone did not improve the response rate when combined with cisplatin for patients with advanced NSLC.

KW - Cisplatin

KW - Lung cancer

KW - Mitoxantrone

UR - http://www.scopus.com/inward/record.url?scp=0029923101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029923101&partnerID=8YFLogxK

U2 - 10.1097/00000421-199604000-00021

DO - 10.1097/00000421-199604000-00021

M3 - Article

C2 - 8610648

AN - SCOPUS:0029923101

VL - 19

SP - 190

EP - 192

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -